Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Elite Pharmaceuticals Inc

OTC: ELTP · Life Sciences · 4 alerts · CIK 1053369

Share price
$0.3700Close, Nov 16
Market cap
$399M
Shares outstanding
1.08BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Elite Pharmaceuticals Inc filings on SEC EDGAR ↗

5:20 PM ET 8-K
Financial Results

Elite Pharmaceuticals Financial Results

Elite Pharmaceuticals reported financial results for its second fiscal quarter ended September 30, 2026, with revenue increasing 10.4% to $40.1 million. The growth was driven by the company's Elite label amphetamine and naltrexone product lines, leading to a 21% increase in operating income to $9.9 million.

Term
Q2 2027
4:07 PM ET 10-Q
Financial Results

Elite Pharmaceuticals Q2 2026 Results: Net Income $17.3M, Up 26.4% YoY

Elite Pharmaceuticals reported net income of $23.2 million for the six months ended September 30, 2026, a significant increase from $7.8 million in the prior year period, largely driven by a $9.8 million gain from the change in fair value of derivative warrants. While six-month revenue slightly decreased to $72.4 million, the company maintained a strong cash position of $34.9 million and significantly reduced its total liabilities from $39.4 million to $22.1 million.

Key figure
Net income $17.3M · +26.4% YoY

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.